相关实验视频
Updated: Jul 11, 2026

08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
内源性氧化合成酶抑制剂:一种新的动脉样硬化标志物
H Miyazaki1, H Matsuoka, J P Cooke
1Department of Internal Medicine III and the Cardiovascular Research Institute, Kurume University School of Medicine Matsuoka, Kurume, Japan.
Circulation
|March 9, 1999
概括
不对称二甲基氨基 (ADMA) 的血水平与动脉样硬化风险因素和心动脉内膜-介质厚度相关. 这表明ADMA可能作为检测动脉样硬化的潜在生物标志物.
科学领域:
- 心血管研究研究心血管研究
- 生物标志物发现发现
- 内皮细胞功能 内皮细胞功能
背景情况:
- 高血压和高胆固醇血症降低了氧化 (NO) 的生物可用性,损害了血管扩张.
- 非对称二甲基氨基 (ADMA) 是一种内源的NO合成酶抑制剂,在人体血中发现.
- 研究ADMA在动脉样硬化中的作用对于了解血管健康至关重要.
研究的目的:
- 为了确定血ADMA水平和人类动脉样硬化之间的关联.
- 探索ADMA与已确定的动脉样硬化风险因素的相关性.
- 评估ADMA与亚临床动脉样硬化标志物的关系.
主要方法:
- 116名没有心血管疾病的受试者接受了临床评估,血清化学和血ADMA水平的确定.
- 双重超声波用于测量动脉内心介质厚度.
- 统计分析包括单变量,多变量和逐步回归.
主要成果:
- 血ADMA水平与年龄,平均动脉压和葡萄糖耐受性有正相关性.
- 在血ADMA度和动脉内膜-介质厚度之间发现了显著的正相关性.
- ADMA水平与动脉样硬化发展的关键风险因素有关.
结论:
- 血ADMA水平与动脉样硬化风险因素积极相关.
- 血ADMA的升高与动脉内膜-介质厚度的增加显著相关.
- 不对称的二甲基氨基可能作为动脉样硬化的一个有价值的生物标志物.
更多相关视频
相关概念视频
Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

